Generic drug

Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Saturday, May 23, 2020 - 12:15am

However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations.

Key Points: 
  • However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations.
  • The global antiviral drugs market is fragmented into branded drugs and generic drugs.
  • Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers.
  • The report provides a comprehensive analysis of the global antiviral drugs market.

Insights into the Worldwide Antiviral Drugs Industry to 2024 - Potential Impact of COVID-19 - ResearchAndMarkets.com

Friday, May 22, 2020 - 2:55pm

The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global antiviral drugs market is expected to reach US$ 70.95 billion in 2024, increasing at a CAGR of 2.10%, for the duration of 2020-2024.
  • The global antiviral drugs market is fragmented into branded drugs and generic drugs.
  • Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers.

First UK Participant Enters the Largest COVID-19 Interventional Trial in the World Involving 40,000 Frontline Healthcare Workers

Thursday, May 21, 2020 - 6:00am

Over 130 UK frontline healthcare workers have lost their lives from COVID-19[1] and this study will test if hydroxychloroquine/chloroquine can be used to effectively protect our valued frontline medical staff, allowing them to undertake their vital roles more safely.

Key Points: 
  • Over 130 UK frontline healthcare workers have lost their lives from COVID-19[1] and this study will test if hydroxychloroquine/chloroquine can be used to effectively protect our valued frontline medical staff, allowing them to undertake their vital roles more safely.
  • Accord Healthcare, a UK-based medicines manufacturer, has donated over two million tablets to enable this landmark trial to go ahead.
  • A large-scale, prospective, randomised, double-blind clinical trial in a high-risk setting is the only way to robustly determine if this medicine can lessen or prevent human infection.
  • We have one of the largest market footprints of any European generic company, selling generic medicines in over 80 countries around the world.

Cipla Files ANDA for Generic Version of GSK's Advair Diskus®

Tuesday, May 19, 2020 - 11:00am

The product is the generic version of GSK's Advair Diskus.

Key Points: 
  • The product is the generic version of GSK's Advair Diskus.
  • According to IQVIA (IMS Health), Advair Diskus and its generic equivalents had US sales of approximately US $2.9bn for the 12-month period ending March 2020.
  • Commenting on the filing, Mr. Umang Vohra (MD and Global CEO, Cipla Limited)said, "We are pleased to announce the ANDA submission for generic Advair Diskus to the USFDA.
  • Cipla's borderless respiratory program, a slew of new devices launches and the ANDA filing of generic Advair Diskus are in line with its goal of becoming a global lung leader.

Osmotica Pharmaceuticals plc to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Wednesday, May 13, 2020 - 10:08pm

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.

Key Points: 
  • The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Osmotica Pharmaceuticals plc to Provide First Quarter 2020 Business and Financial Update on May 12, 2020

Friday, May 8, 2020 - 6:30pm

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.

Key Points: 
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Role of Pharmacovigilance in Precision Medicine Market

Friday, May 8, 2020 - 2:00pm

According to Quantzigs pharmacovigilance experts, To succeed in todays precision medicine market, one must overcome the challenges facing the sector by devising appropriate strategies to skillfully tackle unfavorable situations.

Key Points: 
  • According to Quantzigs pharmacovigilance experts, To succeed in todays precision medicine market, one must overcome the challenges facing the sector by devising appropriate strategies to skillfully tackle unfavorable situations.
  • The client is a leading player in the German precision medicine market, offering a diverse portfolio of products for both treatment and prevention of diseases, including prescription drugs, generics, and other solutions targeted at both the physician and individual consumer-level.
  • With pain management and addiction drugs being new focus areas, the client decided to leverage pharmacovigilance analytics by partnering with Quantzig to build a robust pharmacovigilance analytics process.
  • This allows companies operating in the precision medicine market to quickly review clinical data and develop targeted drugs by leveraging an improved drug development and safety monitoring process.

Generic ED Drug Prices Drop, Branded Drug Prices Rise During COVID-19

Tuesday, May 5, 2020 - 6:32pm

Generic drug prices continued to fall between January and February 2020, with Tadalafil daily, the generic drug for Cialis Daily, experiencing the sharpest decline at 22.96%.

Key Points: 
  • Generic drug prices continued to fall between January and February 2020, with Tadalafil daily, the generic drug for Cialis Daily, experiencing the sharpest decline at 22.96%.
  • As branded drug prices rise, its important for patients to have access to affordable prescription medications.
  • eDrugstore.com offers cost-effective branded and generic ED medications online.
  • And we will continue monitoring prescription prices to see if they hold insights for drug prices in general during COVID-19.

Blue-Zone Technologies Ltd. Receives Drug Approval From Health Canada for Its Branded Generic DESFLURANE, USP.

Wednesday, April 29, 2020 - 4:33pm

Blue-Zone Technologies Ltd. (Blue-Zone) announces receipt from Health Canada of a Drug Identification Number (DIN) for DESFLURANE, USP, an important drug used for general anesthesia.

Key Points: 
  • Blue-Zone Technologies Ltd. (Blue-Zone) announces receipt from Health Canada of a Drug Identification Number (DIN) for DESFLURANE, USP, an important drug used for general anesthesia.
  • The DIN permits Blue-Zone to produce and commercially launch its branded generic drug.
  • This is the first known approval in the world for a drug produced using a distillation-based process.
  • Health Canada has approved our validated technology which clears the way for our drug approval in a number of large, targeted foreign jurisdictions, she said.

Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)

Tuesday, April 28, 2020 - 9:05pm

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent applications covering the formulation of the 72 mcg dose of LINZESS (linaclotide) and methods of using the formulation.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent applications covering the formulation of the 72 mcg dose of LINZESS (linaclotide) and methods of using the formulation.
  • The vast majority of patent applications that receive a notice of allowance will proceed to issue as a U.S. patent; however, a notice of allowance is not a guarantee of patent issuance.
  • The settlement with Teva does not grant any license to Teva with regard to its 72 mcg generic version of LINZESS.
  • Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients, and in